Navigation Links
Miscarriage and infertility treatment increase pre-eclampsia risk
Date:12/18/2008

pment of the pregnancy. Failure in the development and function of the placenta seems to be an important mechanism in the development of pre-eclampsia but no-one knows why. The results from this study show that the protective effect seen after earlier normal pregnancies (births or terminations) is not present among women with repeated miscarriages. The study indicates that common causal factors linked to the placenta's development and function may be present in infertility, repeated miscarriages and pre-eclampsia.

Facts about pre-eclampsia

  • Affects 3-5 % of all pregnant women.
  • Greatest risk among first-time mothers.
  • Appears in second half of pregnancy
  • Recognised by high blood pressure and protein in mother's urine.
  • In mild cases the mother can be unaffected by the condition, but in serious cases, pre-eclampsia can be life-threatening for mother and baby, with organ failure and danger of seizures among mothers.
  • The child risks poor growth and development due to insufficient placenta function.
  • The only treatment is delivery of baby and placenta.
  • Pre-eclampsia is therefore an important cause of premature birth.
  • Among women who have given birth earlier, the risk is approximately halved. The same applies to women who have had earlier terminations. It is unknown why earlier normal pregnancies protect against pre-eclampsia in later pregnancies.


'/>"/>

Contact: Media Contact
julie.johansen@fhi.no
Norwegian Institute of Public Health
Source:Eurekalert

Page: 1 2

Related biology news :

1. Statins may prevent miscarriages
2. Proteins in sperm unlock understanding of male infertility says new study
3. Diabetes linked to male infertility; excess sugars in the body have direct effect on sperm quality
4. USC researchers explore genetic causes for male infertility
5. UC Davis team refines cancer treatments to reduce potential nerve damage
6. In just 5 years, gene discovery to clinical trial of potential treatment
7. Leeds research points to new therapy for hepatitis C treatment
8. Epilepsy drug shows potential for Alzheimers treatment
9. First trial in patients with a potential treatment of the incurable ALS muscle disease
10. Scientists developing food allergy treatment
11. Inherited genetic cause, possible treatment found for complex lung disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... of British Columbia and the Child & Family Research Institute ... a type of T cell in type 1 diabetes that ... Also known as juvenile diabetes, type 1 diabetes is an ... with type 1 diabetes, the body attacks itself by destroying ...
... to the National Heart, Lung and Blood Institute, the average ... and 30 times a night. This lack of oxygen leads ... disease, an abnormal heart rhythm, or even a fatal cardiac ... exploring the changes in distinct brain regions that contribute to ...
... The National Institute of Environmental Health Sciences has ... Shaw for a five-year study of how the ... selection. The project reflects a changing ... advances in molecular toxicology, computational sciences and information ...
Cached Biology News:Researchers study sleep apnea and lack of oxygen 2Researcher awarded $2.27 million to study environmental effects on gene copy number 2Researcher awarded $2.27 million to study environmental effects on gene copy number 3Researcher awarded $2.27 million to study environmental effects on gene copy number 4
(Date:7/30/2015)... ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online contractor management ... over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Dallas, TX , ISN has additional offices in Calgary , ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... applications and designed for continuous operation up to 1500 bar. The sanitary design ... efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal ...
(Date:7/29/2015)... 2015: +14% CER / 20% of sales) led the regional performance in the ... as well as solid contributions from Korea, India and ... Middle East / Africa (Q2 2015: +3% ... Turkey and the United Kingdom . ... U.S. HPV sales, on demand across all customer classes. The top seven emerging ...
(Date:7/29/2015)... 29, 2015 Research ... addition of the "Global Biosimilars Market, 2015 ... The Global Biosimilars Market, 2015 - 2025, ... growing biosimilars market. With the blockbuster biologics losing ... costs, biosimilars are being viewed as viable substitutes ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
... deCODE genetics,(Nasdaq: DCGN ) today ... laboratory, which processes the company,s deCODEme(TM) personal,genome ... several common,diseases, has been accredited by the ... inspection. The U.S. Centers for Medicare and ...
... to Launch into High Growth Brazilian Market for ... Aesthera announced today the receipt of ANVISA clearance ... platforms in Brazil. ANVISA (Agencia Nacional de ... and regulatory agency charged with clearing all applications ...
... in Groton , Connecticut MORRISVILLE, ... contract manufacturer of APIs, intermediates and Drug Products to the ... pleased to announce the recent award by Pfizer Inc. as ... at Pfizer,s Groton, Connecticut R&D center on May 1, 2009. ...
Cached Biology Technology:deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 2deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 3deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 4Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 2Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 3Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem 2
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... component of the COP9 signalosome complex (CSN), ... developmental processes. The CSN complex is an ... pathway by mediating the deneddylation of the ... The complex is also involved in phosphorylation ...
... STAR3000 HISTAR detection systems provide linking ... used with species specific primary antibodies ... specimens. Visualisation is accomplished using an ... novel polymer labelling technology. Secondary antibodies ...
Request Info...
Biology Products: